138 related articles for article (PubMed ID: 29207934)
1. Incidence of skeletal related events in patients with bone metastasis receiving denosumab every four weeks compared to intervals greater than every four weeks.
Yerram P; Moore R; Wolf S; Barbour SY
J Oncol Pharm Pract; 2019 Apr; 25(3):529-534. PubMed ID: 29207934
[TBL] [Abstract][Full Text] [Related]
2. Incidence of hypocalcemia in patients receiving denosumab for prevention of skeletal-related events in bone metastasis.
Yerram P; Kansagra S; Abdelghany O
J Oncol Pharm Pract; 2017 Apr; 23(3):179-184. PubMed ID: 26830549
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of bone-modifying agents among multiple myeloma patients: A retrospective cohort study.
Billias C; Langer M; Ursu S; Schorr R
J Oncol Pharm Pract; 2022 Apr; 28(3):523-529. PubMed ID: 33593137
[TBL] [Abstract][Full Text] [Related]
4. Effect of denosumab versus zoledronic acid on calcium levels in cancer patients with bone metastasis: A retrospective cohort study.
Nasser SM; Sahal A; Hamad A; Elazzazy S
J Oncol Pharm Pract; 2019 Dec; 25(8):1846-1852. PubMed ID: 31694497
[TBL] [Abstract][Full Text] [Related]
5. Prospective observational study to evaluate the persistence of treatment with denosumab in patients with bone metastases from solid tumors in routine clinical practice: final analysis.
Haslbauer F; Petzer A; Safanda M; Tomova A; Porubska M; Bajory Z; Niepel D; Jaeger C; Bjorklof K; Kalinin D; Greil R
Support Care Cancer; 2020 Apr; 28(4):1855-1865. PubMed ID: 31350601
[TBL] [Abstract][Full Text] [Related]
6. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
Raje N; Terpos E; Willenbacher W; Shimizu K; García-Sanz R; Durie B; Legieć W; Krejčí M; Laribi K; Zhu L; Cheng P; Warner D; Roodman GD
Lancet Oncol; 2018 Mar; 19(3):370-381. PubMed ID: 29429912
[TBL] [Abstract][Full Text] [Related]
7. Severe Hypocalcemia Associated With Denosumab in Metastatic Castration-Resistant Prostate Cancer: Risk Factors and Precautions for Treating Physicians.
Autio KA; Farooki A; Glezerman IG; Chan A; Schneider CW; Barr HC; Seyboth BM; Kampel LJ; Danila DC; Rathkopf DE; Slovin SF; Scher HI; Morris MJ
Clin Genitourin Cancer; 2015 Aug; 13(4):e305-e309. PubMed ID: 25559408
[No Abstract] [Full Text] [Related]
8. Feasibility of extended dosing intervals of denosumab.
Kettle JK; Patel PB
J Oncol Pharm Pract; 2018 Jul; 24(5):343-347. PubMed ID: 28393590
[TBL] [Abstract][Full Text] [Related]
9. Denosumab in hypercalcemia of malignancy: a case series.
Dietzek A; Connelly K; Cotugno M; Bartel S; McDonnell AM
J Oncol Pharm Pract; 2015 Apr; 21(2):143-7. PubMed ID: 24415364
[TBL] [Abstract][Full Text] [Related]
10. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab.
Loyson T; Van Cann T; Schöffski P; Clement PM; Bechter O; Spriet I; Coropciuc R; Politis C; Vandeweyer RO; Schoenaers J; Dumez H; Berteloot P; Neven P; Nackaerts K; Woei-A-Jin FJSH; Punie K; Wildiers H; Beuselinck B
Acta Clin Belg; 2018 Apr; 73(2):100-109. PubMed ID: 28693379
[TBL] [Abstract][Full Text] [Related]
11. Denosumab-Associated Severe Hypocalcemia in a Patient With Chronic Kidney Disease.
Salim SA; Nair LR; Thomas L; Garla V; Palabindala V; Agarwal M; Fülöp T
Am J Med Sci; 2018 May; 355(5):506-509. PubMed ID: 29753381
[TBL] [Abstract][Full Text] [Related]
12. Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review.
Takahashi M; Ozaki Y; Kizawa R; Masuda J; Sakamaki K; Kinowaki K; Umezu T; Kondoh C; Tanabe Y; Tamura N; Miura Y; Shigekawa T; Kawabata H; Baba N; Iguchi H; Takano T
BMC Cancer; 2019 Oct; 19(1):980. PubMed ID: 31640606
[TBL] [Abstract][Full Text] [Related]
13. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases.
Lipton A; Steger GG; Figueroa J; Alvarado C; Solal-Celigny P; Body JJ; de Boer R; Berardi R; Gascon P; Tonkin KS; Coleman R; Paterson AH; Peterson MC; Fan M; Kinsey A; Jun S
J Clin Oncol; 2007 Oct; 25(28):4431-7. PubMed ID: 17785705
[TBL] [Abstract][Full Text] [Related]
14. Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer.
Stopeck AT; Fizazi K; Body JJ; Brown JE; Carducci M; Diel I; Fujiwara Y; Martín M; Paterson A; Tonkin K; Shore N; Sieber P; Kueppers F; Karsh L; Yardley D; Wang H; Maniar T; Arellano J; Braun A
Support Care Cancer; 2016 Jan; 24(1):447-455. PubMed ID: 26335402
[TBL] [Abstract][Full Text] [Related]
15. Tolerability of denosumab in metastatic solid tumor patients with renal insufficiency.
Watkins KR; Rogers JE; Atkinson B
Support Care Cancer; 2015 Jun; 23(6):1657-62. PubMed ID: 25421444
[TBL] [Abstract][Full Text] [Related]
16. A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America.
Raje N; Roodman GD; Willenbacher W; Shimizu K; García-Sanz R; Terpos E; Kennedy L; Sabatelli L; Intorcia M; Hechmati G
J Med Econ; 2018 May; 21(5):525-536. PubMed ID: 29480139
[TBL] [Abstract][Full Text] [Related]
17. High serum ALP level is associated with increased risk of denosumab-related hypocalcemia in patients with bone metastases from solid tumors.
Kinoshita Y; Arai M; Ito N; Takashi Y; Makita N; Nangaku M; Shinoda Y; Fukumoto S
Endocr J; 2016 May; 63(5):479-84. PubMed ID: 26860123
[TBL] [Abstract][Full Text] [Related]
18. Hypocalcaemia in patients with metastatic bone disease treated with denosumab.
Body JJ; Bone HG; de Boer RH; Stopeck A; Van Poznak C; Damião R; Fizazi K; Henry DH; Ibrahim T; Lipton A; Saad F; Shore N; Takano T; Shaywitz AJ; Wang H; Bracco OL; Braun A; Kostenuik PJ
Eur J Cancer; 2015 Sep; 51(13):1812-21. PubMed ID: 26093811
[TBL] [Abstract][Full Text] [Related]
19. Denosumab-induced hypocalcemia in patients with solid tumors and renal dysfunction: a multicenter, retrospective, observational study.
Nakamura K; Kaya M; Yanagisawa Y; Yamamoto K; Takayashiki N; Ukita H; Nagura M; Sugiue K; Kitajima M; Hirano K; Ishida H; Onoda C; Kobayashi Y; Nakatani E; Odagiri K; Suzuki T
BMC Cancer; 2024 Feb; 24(1):218. PubMed ID: 38360579
[TBL] [Abstract][Full Text] [Related]
20. Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics.
Lipton A; Fizazi K; Stopeck AT; Henry DH; Smith MR; Shore N; Martin M; Vadhan-Raj S; Brown JE; Richardson GE; Saad F; Yardley DA; Zhou K; Balakumaran A; Braun A
Eur J Cancer; 2016 Jan; 53():75-83. PubMed ID: 26693901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
